ProfileGDS5678 / 1434610_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 90% 88% 90% 86% 89% 89% 89% 87% 86% 87% 87% 87% 89% 89% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.0796790
GSM967853U87-EV human glioblastoma xenograft - Control 26.8254588
GSM967854U87-EV human glioblastoma xenograft - Control 37.2856890
GSM967855U87-EV human glioblastoma xenograft - Control 46.6551186
GSM967856U87-EV human glioblastoma xenograft - Control 57.0710389
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.8600389
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.909989
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.5655987
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.4318786
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.7733387
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.7222487
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.698987
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.9553189
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.9833389